Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Pomalidomide

Review the clinical trials studying pomalidomide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 28

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Status: Active
Location: 28 locations
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Status: Active
Location: 16 locations
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 14 locations
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Status: Active
Location: 14 locations
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Status: Active
Location: 12 locations
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Status: Active
Location: 10 locations
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Status: Active
Location: 9 locations
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 8 locations
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Status: Active
Location: 12 locations
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 4 locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Status: Active
Location: 7 locations
A Study of Daratumumab
Status: Active
Location: 3 locations
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Status: Active
Location: 5 locations
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Status: Active
Location: 3 locations
Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Status: Active
Location: 3 locations
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 3 locations
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Status: Active
Location: 4 locations
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Status: Active
Location: 2 locations
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Status: Active
Location: 2 locations
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Belantamab Mafodotin in Combination with Carfilzomib, Pomalidomide, and Dexamethasone for Treatment of Relapsed or Recurrent Multiple Myeloma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma
Status: Active
Location: See ClinicalTrials.gov
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina